news – Page 77 – Medxy AI

Deferred Cord Clamping with High Oxygen in Extremely Preterm Infants: Enhancing Early Oxygenation Without Added Morbidity

By MedXY 09/10/2025

This review examines randomized clinical evidence that 100% oxygen during deferred cord clamping improves early oxygen saturation in extremely preterm infants without increasing morbidity, highlighting implications for neonatal resuscitation practice.

Cardiology Diabetes & Endocrinology news Specialties

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY 09/10/2025

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

news OB/GYN & Women's Health Pediatrics Specialties

In Utero Embolization for Fetal Vein of Galen Malformation: Early Clinical Insights and Outcomes

By MedXY 09/10/2025

This article reviews early clinical results from a US single-center study on in utero embolization for fetal Vein of Galen malformation, highlighting potential survival benefits alongside risks of preterm delivery.

Family Medicine & Nutrition news Specialties

Human Telephone vs. Text Message Counseling: Increasing Physical Activity in Midlife and Older Hispanic Adults

By MedXY 09/10/2025

A randomized clinical trial demonstrates that customizable SMS counseling is as effective as human telephone counseling in increasing 12-month walking activity among inactive Hispanic or Latino/a adults, offering scalable options for public health interventions.

Clinical Updates Neurology news OB/GYN & Women's Health Specialties

Innovations in Prenatal Care: In Utero Embolization for Vein of Galen Malformation

By MedXY 09/10/2025

In utero embolization for fetal Vein of Galen malformation shows early promise in reducing mortality and neurodevelopmental delays, despite increased risk of preterm delivery.

Cardiology Clinical Updates news Nursing & care Specialties

Multidomain Rehabilitation Reduces Cardiovascular Events in Older Adults Post-Myocardial Infarction: Insights from the PIpELINe Trial

By MedXY 09/10/2025

A multidomain rehabilitation program combining cardiovascular risk control, dietary counseling, and exercise significantly lowers the risk of cardiovascular death or unplanned hospitalization within one year in older myocardial infarction survivors with impaired physical performance.

Cardiology news Specialties

Evaluating Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial

By MedXY 09/10/2025

A phase 3 trial found mavacamten did not significantly improve exercise capacity or symptoms in adults with symptomatic nonobstructive hypertrophic cardiomyopathy compared to placebo, despite its efficacy in obstructive HCM.

news Respiratory Specialties

Evaluating Carbocysteine in Mild-to-Moderate COPD: Insights From a Large Multicenter Controlled Trial

By MedXY 09/10/2025

A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.

Diabetes & Endocrinology news Specialties

Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes: A Comprehensive Review of Randomized Controlled Trial Evidence and Clinical Implications

By MedXY 09/10/2025

Automated insulin delivery (AID) significantly improves glycemic control in insulin-treated type 2 diabetes, demonstrating greater HbA1c reduction and increased time in target glucose range compared to traditional insulin delivery methods.

Clinical Updates Hematology-Oncology news Pathology & Lab Medicine Specialties

Ultrasensitive Circulating Tumor DNA as a Superior Biomarker for Remission Assessment in Large B-cell Lymphoma

By MedXY 09/10/2025

Detection of circulating tumor DNA (ctDNA) provides a highly prognostic method for assessing remission in large B-cell lymphoma, outperforming conventional imaging and promising improved patient outcomes.

Clinical Updates Hematology-Oncology news Specialties

Reversing PD-1 Resistance in Advanced Melanoma: Insights from the SPOTLIGHT-203 Phase II Trial of BO-112 Plus Pembrolizumab

By MedXY 09/10/2025

The SPOTLIGHT-203 Phase II trial demonstrates that intratumoral BO-112 combined with pembrolizumab shows promise by achieving a 25% ORR in anti-PD-1-resistant advanced melanoma with manageable safety, offering a potential new therapeutic avenue.

Clinical Updates news Oncology Specialties

Prognostic Role of HER2 Amplification and Mutations in Metastatic Colorectal Cancer: Insights from Eight Randomized Trials

By MedXY 09/10/2025

HER2 amplification/mutation in RAS/BRAF wild-type metastatic colorectal cancer is a negative prognostic factor but does not predict differential benefit from bevacizumab or anti-EGFR therapies, based on analysis of 1,604 patients across eight randomized trials.

news Oncology Specialties

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2: Clinical Advances and Therapeutic Implications

By MedXY 09/10/2025

Phase 3 trials demonstrate that encapsulated cell therapy NT-501 significantly slows photoreceptor loss in MacTel, marking a promising disease-modifying approach with an acceptable safety profile.

Medical News news

Marathon Running and Cancer Risk: Separating Fact from Fiction

By MedXY 09/09/2025

Recent studies suggest a potential link between extreme marathon running and increased colorectal cancer risk, but research is preliminary and applies to rare cases. For most people, moderate exercise remains beneficial and safe.

Clinical Updates news Oncology Specialties

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

By MedXY 09/09/2025

The KEYNOTE-585 trial adding pembrolizumab to perioperative chemotherapy did not significantly improve event-free survival in esophagogastric cancer, while the MATTERHORN trial showed durvalumab plus FLOT chemotherapy improves outcomes, establishing a new standard of care.

Clinical Updates Hematology-Oncology news Specialties

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

By MedXY 09/09/2025

Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against approved doublet therapies.

$Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up$

Clinical Updates Hematology-Oncology news Specialties

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up

By MedXY 09/09/2025

The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory large B-cell lymphoma.

$Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1$

Clinical Updates Hematology-Oncology news Specialties

Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1

By MedXY 09/09/2025

CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a favorable safety profile.

Clinical Updates news Oncology Specialties

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

By MedXY 09/09/2025

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and treatment duration implications.

Clinical Updates Hematology-Oncology news Specialties Transplantation

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

By MedXY 09/09/2025

Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for underrepresented patient groups.